BioCryst Pharmaceuticals, Inc. (BCRX)
9.70
-0.11
(-1.12%)
USD |
NASDAQ |
Mar 20, 16:00
10.04
+0.34
(+3.51%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly) : 40.47M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 6.452M |
| Lantheus Holdings, Inc. | 47.48M |
| Revolution Medicines, Inc. | 292.61M |
| Plus Therapeutics, Inc. | 2.941M |
| BioStem Technologies, Inc. | 1.958M |